Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biotech company, has announced its participation in the upcoming Sidoti August Virtual Investor Conference. Han Ying, PhD, the company's CEO, will present a company overview on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT).
Gyre Therapeutics is known for its self-sustainable approach and focuses on developing treatments for various chronic organ diseases. Interested parties can register in advance for the presentation webcast. For those unable to attend live, a replay will be available on the Events and Presentations page of Gyre's website following the session.
Gyre Therapeutics (Nasdaq: GYRE), un'azienda biotech in fase commerciale, ha annunciato la sua partecipazione alla prossima Sidoti August Virtual Investor Conference. Han Ying, PhD, CEO dell'azienda, presenterà una panoramica della compagnia giovedì 15 agosto 2024, alle 10:45 ET (7:45 PT).
Gyre Therapeutics è conosciuta per il suo approccio auto-sostenibile e si concentra sullo sviluppo di trattamenti per varie malattie croniche degli organi. Le parti interessate possono registrarsi in anticipo per la trasmissione in webcast della presentazione. Per coloro che non possono partecipare dal vivo, sarà disponibile una registrazione sulla pagina Eventi e Presentazioni del sito web di Gyre dopo la sessione.
Gyre Therapeutics (Nasdaq: GYRE), una empresa biotecnológica en etapa comercial, ha anunciado su participación en la próxima Sidoti August Virtual Investor Conference. Han Ying, PhD, el CEO de la empresa, presentará una visión general de la compañía el jueves 15 de agosto de 2024, a las 10:45 a.m. ET (7:45 a.m. PT).
Gyre Therapeutics es conocida por su enfoque autosostenible y se centra en el desarrollo de tratamientos para diversas enfermedades crónicas de los órganos. Las partes interesadas pueden registrarse con anticipación para la transmisión por webcast de la presentación. Para aquellos que no pueden asistir en vivo, habrá una recreación disponible en la página de Eventos y Presentaciones del sitio web de Gyre después de la sesión.
Gyre Therapeutics (Nasdaq: GYRE)는 상업 단계에 있는 생명공학 회사로, 다가오는 Sidoti August Virtual Investor Conference에 참가할 것이라고 발표했습니다. Han Ying, PhD는 회사의 CEO로서 2024년 8월 15일 목요일 오전 10:45 ET (오전 7:45 PT)에 회사 개요를 발표할 예정입니다.
Gyre Therapeutics는 자급 자족적인 접근 방식으로 알려져 있으며, 다양한 만성 장기 질환 치료법 개발에 주력하고 있습니다. 관심 있는 분들은 발표 웹캐스트를 미리 등록할 수 있습니다. 실시간 참석이 불가능한 분들을 위해, 세션 후 Gyre 웹사이트의 이벤트 및 발표 페이지에서 다시 보기가 제공됩니다.
Gyre Therapeutics (Nasdaq: GYRE), une entreprise biotech en phase commerciale, a annoncé sa participation à la prochaine Sidoti August Virtual Investor Conference. Han Ying, PhD, PDG de l'entreprise, présentera un aperçu de l'entreprise jeudi 15 août 2024 à 10h45 ET (7h45 PT).
Gyre Therapeutics est connue pour son approche autosuffisante et se concentre sur le développement de traitements pour diverses maladies chroniques des organes. Les parties intéressées peuvent s'inscrire à l'avance pour le webinaire de présentation. Pour ceux qui ne peuvent pas assister en direct, un enregistrement sera disponible sur la page Événements et Présentations du site Web de Gyre après la session.
Gyre Therapeutics (Nasdaq: GYRE), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat seine Teilnahme an der bevorstehenden Sidoti August Virtual Investor Conference angekündigt. Han Ying, PhD, der CEO des Unternehmens, wird am Donnerstag, den 15. August 2024, um 10:45 Uhr ET (7:45 Uhr PT) eine Unternehmensübersicht präsentieren.
Gyre Therapeutics ist bekannt für seinen selbsttragenden Ansatz und konzentriert sich auf die Entwicklung von Behandlungen für verschiedene chronische Organerkrankungen. Interessierte können sich im Voraus für die Präsentations-Webcast registrieren. Für diejenigen, die nicht live teilnehmen können, wird eine Aufzeichnung nach der Sitzung auf der Seite für Veranstaltungen und Präsentationen der Gyre-Website verfügbar sein.
- None.
- None.
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the Sidoti August Virtual Investor Conference on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT).
To register in advance for the presentation webcast, sign up here.
A webcast replay will be accessible following the live session on the Events and Presentations page of Gyre’s website.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.
For Investors:
Stephen Jasper
FAQ
When is Gyre Therapeutics (GYRE) presenting at the Sidoti Virtual Investor Conference?
Who will be presenting for Gyre Therapeutics (GYRE) at the Sidoti conference?
How can I watch Gyre Therapeutics' (GYRE) presentation at the Sidoti conference?
What is the focus of Gyre Therapeutics' (GYRE) clinical development programs?
